Sharp, a contract packaging specialist for clinical supply services and small-scale sterile manufacturing, has announced plans for the expansion of its Macungie, PA site in the US to increase its production capacity for sterile injectables secondary packaging.
The expansion at Macungie will offer increased capacity for secondary packaging activities including vial labelling, pre-filled syringe assembly and labelling, autoinjector/pen assembly & labelling and injectables kitting and cartoning for pharmaceutical and biotech companies.
This latest investment at Macungie follows the recent addition of a 660 pallet 2-8 ˚C cold box, which was commissioned at the end of April.
The expansion adds 157,500 sqft of open space to create a 315,000 sqft facility, bringing Sharp’s total global footprint to more than 1.7m sqft.
Jeff Benedict, Chief Commercial Officer at Sharp, commented: “Demand for sterile injectable medicines has skyrocketed over the last few years due to increased investment in the biologics industry across all therapeutic categories, rare and orphan disease therapies and blockbuster GLP-1 agonists. With this expansion, the Macungie site will double in size allowing Sharp to offer additional capacity and capabilities for our biopharma clients for complex biologics and small-molecule injectable medicines."
The expansion follows reports that the sterile injectable market is forecasted to grow at a CAGR of 8% over the next 10 years to reach $5.7 Billion by 2030. (1)
Plans include the construction and fit-out of new packaging suites, ambient warehouse space, cold storage rooms as well as equipment and technology to support assembly, labelling and packaging of injectables.
